- Home
- MRCC vs SCPH Comparison
MRCC vs SCPH Comparison
Compare MRCC & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRCC
- SCPH
- Stock Information
- Founded
- MRCC 2011
- SCPH 2013
- Country
- MRCC United States
- SCPH United States
- Employees
- MRCC N/A
- SCPH N/A
- Industry
- MRCC Investment Managers
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- MRCC Finance
- SCPH Health Care
- Exchange
- MRCC Nasdaq
- SCPH Nasdaq
- Market Cap
- MRCC 176.4M
- SCPH 173.6M
- IPO Year
- MRCC 2012
- SCPH 2017
- Fundamental
- Price
- MRCC $6.50
- SCPH $4.06
- Analyst Decision
- MRCC Hold
- SCPH Strong Buy
- Analyst Count
- MRCC 1
- SCPH 3
- Target Price
- MRCC $8.00
- SCPH $14.00
- AVG Volume (30 Days)
- MRCC 87.0K
- SCPH 251.2K
- Earning Date
- MRCC 08-06-2025
- SCPH 08-13-2025
- Dividend Yield
- MRCC 15.82%
- SCPH N/A
- EPS Growth
- MRCC 3301.50
- SCPH N/A
- EPS
- MRCC 0.32
- SCPH N/A
- Revenue
- MRCC $56,983,000.00
- SCPH $41,982,000.00
- Revenue This Year
- MRCC N/A
- SCPH $108.95
- Revenue Next Year
- MRCC N/A
- SCPH $73.83
- P/E Ratio
- MRCC $19.45
- SCPH N/A
- Revenue Growth
- MRCC N/A
- SCPH 138.10
- 52 Week Low
- MRCC $6.11
- SCPH $1.94
- 52 Week High
- MRCC $8.85
- SCPH $5.65
- Technical
- Relative Strength Index (RSI)
- MRCC 52.60
- SCPH 59.89
- Support Level
- MRCC $6.19
- SCPH $3.83
- Resistance Level
- MRCC $6.65
- SCPH $4.14
- Average True Range (ATR)
- MRCC 0.15
- SCPH 0.16
- MACD
- MRCC 0.02
- SCPH -0.03
- Stochastic Oscillator
- MRCC 67.71
- SCPH 81.40
About MRCC Monroe Capital Corporation
Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.